A Phase 1/2a Double-Blind, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Oral Administration of the Phage Cocktail, VRELysin™, In Healthy And VRE-Colonized Subjects

The study is a first-in-human Phase 1/2a randomized, double-blind, placebo-controlled trial to assess the clinical safety and efficacy of VRELysin in healthy and VRE-colonized adults.

开始日期2023-10-25

申办/合作机构

Intralytix, Inc.

NCT05182749 / Active, not recruiting临床1/2期

A Phase 1/2a Double-Blind, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Oral Administration of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis With Shigella Flexneri 2a Strain

The study is a first-in-human Phase 1/2a randomized, double-blind, placebo-controlled trial to assess the clinical safety and efficacy of ShigActive in healthy adults with experimental Shigella challenge.

开始日期2023-02-23

申办/合作机构

Intralytix, Inc.

[+1]

NCT03808103 / Recruiting临床1/2期

A Phase 1/2a Double-Blind, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Oral Administration of EcoActive on Intestinal Adherent Invasive Escherichia Coli (AIEC) in Patients With Inactive Crohn's Disease (CD)

This study will evaluate the safety of oral administration of EcoActive to patients with inactive Crohn's disease and how it affects the levels of AIEC in stool.

开始日期2019-05-01

申办/合作机构

Intralytix, Inc.

[+2]

100 项与 Intralytix, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Intralytix, Inc. 相关的专利（医药）

登录后查看更多信息

项与 Intralytix, Inc. 相关的文献（医药）

2023-09-01·Journal of Food Protection

Phage Biocontrol Effectively Reduces Contamination of Wheat with Shiga Toxin-producing Escherichia coli O121 and O26 Without Adverse Effects on Flour Quality

Article

作者: Rivera, Jared ; D P, Shivaprasad ; Siliveru, Kaliramesh ; Vikram, Amit

Contamination of wheat flours with Shiga toxin-producing E. coli (STEC) is a concern for the milling industry. Milling-specific interventions are needed to address this food safety hazard. The objectives for this study were to determine the efficacy of bacteriophage treatment in reducing wheat STEC contamination during tempering, and assess its effects on flour milling and baking quality. Bacteriophage solutions were prepared by mixing sterile water with the bacteriophage treatment at the following levels: 1 × 10⁶ (0.1%), 2.5 × 10⁶ (0.25%), 5 × 10⁶ (0.5%), 1 × 10⁷ (1.0%), and 1 × 10⁸ (10%) PFU/g wheat dosage. Sterile water (0%) was used as the control. Predried wheat grains were inoculated with STEC (O121 and O26) at 5.0 and 6.0 log CFU/g to restore its original moisture content followed by resting for 24 h. Inoculated grains were then tempered (16% moisture, 24 h) using the prepared bacteriophage solutions. Grains were sampled at 0.5, 1, 2, 6, 12, 18, and 24 h during tempering to determine STEC concentration. The effects of the phage solutions on the flour milling and baking quality were also tested. Tempering time, bacteriophage dose, and their interaction had significant effects on phage efficacy (P < 0.05), with better reductions observed at longer tempering times and higher bacteriophage doses. The use of phage solutions reduced (P < 0.05) wheat STEC concentration after tempering, with the 10% treatment (3.2 logs) achieving ahigher reduction than the 1% (2.4 logs) treatment under similar phage preparation. Phage tempering (including at the highest concentration examined, i.e., 10%) produced wheat flours with comparable quality to the control. Phage-treated wheat flour resulted in breads with finer crumb structure, and comparable texture compared to the control. Phage tempering is a viable intervention for wheat milling as it reduced STEC loads of wheat with no detrimental effects to flour milling and baking quality.

2022-11-01·Journal of Crohn's and Colitis

Safety and Efficacy of an AIEC-targeted Bacteriophage Cocktail in a Mice Colitis Model

Article

作者: Neut, Christel ; Rahmouni, Oumaïra ; Woolston, Joelle ; Sulakvelidze, Alexander ; Rousseaux, Christel ; Mahieux, Séverine ; Foligné, Benoît ; Titécat, Marie ; Wannerberger, Kristin ; Dubuquoy, Caroline ; Desreumaux, Pierre

AbstractBackground and aimsAdherent invasive Escherichia coli [AIEC] are recovered with a high frequency from the gut mucosa of Crohn’s disease patients and are believed to contribute to the dysbiosis and pathogenesis of this inflammatory bowel disease. In this context, bacteriophage therapy has been proposed for specifically targeting AIEC in the human gut with no deleterious impact on the commensal microbiota.MethodsThe in vitro efficacy and specificity of a seven lytic phage cocktail [EcoActive™] was assessed against [i] 210 clinical AIEC strains, and [ii] 43 non-E. coli strains belonging to the top 12 most common bacterial genera typically associated with a healthy human microbiome. These data were supported by in vivo safety and efficacy assays conducted on healthy and AIEC-colonized mice, respectively.ResultsThe EcoActive cocktail was effective in vitro against 95% of the AIEC strains and did not lyse any of the 43 non-E. coli commensal strains, in contrast to conventional antibiotics. Long-term administration of the EcoActive cocktail to healthy mice was safe and did not induce dysbiosis according to metagenomic data. Using a murine model of induced colitis of animals infected with the AIEC strain LF82, we found that a single administration of the cocktail failed to alleviate inflammatory symptoms, while mice receiving the cocktail twice a day for 15 days were protected from clinical and microscopical manifestations of inflammation.ConclusionsCollectively, the data support the approach of AIEC-targeted phage therapy as safe and effective treatment for reducing AIEC levels in the gut of IBD patients.

2022-02-01·Journal of Food Protection3区 · 农林科学

Evaluation of a Preharvest Bacteriophage Therapy for Control of Salmonella within Bovine Peripheral Lymph Nodes

3区 · 农林科学

Article

作者: Brown, T R ; Sulakvelidze, A ; Wottlin, L R ; Zook, C A ; Droleskey, R ; Edrington, T S ; Genovese, K J ; Nisbet, D J

ABSTRACTA series of proof-of-concept studies were developed to determine whether a commercial bacteriophage cocktail could be utilized for the mitigation of Salmonella in bovine peripheral lymph nodes (LNs). The first objective sought to determine whether exogenous phage could be isolated from the LNs following administration. If isolation were successful, the second objective was to determine whether the phage in the LNs could effectively reduce Salmonella. Salmonella Montevideo was inoculated intradermally at multiple sites and multiple times, followed by delivery of the phage cocktail subcutaneously in two injections around each of the right and left prescapular and subiliac LNs. At the conclusion of each study, animals were euthanized, and the popliteal, prescapular, and subiliac LNs were examined. The inoculated phage was successfully isolated from the LNs; transmission electron microscopy revealed phages in the LNs of the treated cattle, and these phages were identical to those in the cocktail. Levels of phage were higher (P < 0.01) in the prescapular and subiliac LNs in the phage-treated than in the control cattle. In subsequent studies, the protocols were modified to increase Salmonella and phage levels within the LNs. Compared with the first study, overall Salmonella levels were increased in the LNs, and phage treatment decreased (P < 0.01) Salmonella in the some of the LNs. Phage levels were numerically but not significantly increased (P = 0.12) in the treated cattle. The final study was modified, hypothesizing that a 48-h postmortem period before LN removal would facilitate phage-Salmonella interaction; however, no differences (P > 0.10) in Salmonella levels were found among treatments. Salmonella-specific phages administered to live cattle can translocate to the LNs; however, these phages had limited to no effect on Salmonella in these LNs under these experimental conditions.HIGHLIGHTS

项与 Intralytix, Inc. 相关的新闻（医药）

2024-04-04

·动脉网

以色列企业BiomX：聚焦噬菌体疗法，最近为何股价暴涨197%

今年3月6日，以色列噬菌体疗法企业BiomX（纽约证券交易所美国代码：PHGE）宣布与美国噬菌体企业Adaptive Phage Therapeutics（APT）达成最终合并协议，以创建一家全新的生物技术公司。新公司仍将名为 BiomX，BiomX 公司现有股东将持有合并后公司 55% 的股份，其余 45% 由 APT 的股东持有。根据BiomX公司发布的消息显示，合并后的公司还将通过私募渠道新增融资 5000 万美元，用于推进BX004和BX211这两条经过改造的细菌杀伤病毒管线。根据老虎证券显示，消息公布后，BiomX 股价上涨197.66%。后抗生素时代，噬菌体疗法将成主流相较于近几年行业内时常谈论的细胞疗法、基因疗法、核酸疗法、偶联药物等医药细分领域，文首提到的噬菌体疗法似乎显得不那么火热。其实不然，在畅销书《强菌天敌：一个打败致命超级细菌的真实故事》中就讲述了全美第1位、全球文献第1例，使用静脉注射噬菌体成功救命的案例，让人们见识到了噬菌体疗法背后的巨大应用前景。该书讲述了传染病学家Steffanie Strathdee及其丈夫Tom Patterson在埃及度假的过程中，Tom被确诊感染了鲍氏不动桿菌。由于大多数抗生素都无法治疗这种超级多重抗药性细菌，而Tom体内的细菌对仅余有效的三种抗生素也逐渐产生了耐药性。因此，医生们只能寄希望于将致命细菌限制在囊肿内，借由引流管不断吸出当中的感染液，让Tom依靠自身免疫力解决感染。但幸运之神并未眷顾Tom，直到一天，囊肿内的引流管脱落，细菌流出囊肿，若不迅速解决，Tom必死无疑。心急如焚的Steffanie查遍各种疗法，发现抗生素被广泛使用后，渐渐被人们遗忘的噬菌体疗法。Steffanie了解到噬菌体疗法后，迅速向相关的科研人员求救，并寻求FDA的支持。就这样，学界、海军与政界各方人马快马加鞭合作，在3周时间内找到了匹配的噬菌体，并通过静脉直接流入人体血液循环系统，将Tom从死神的手里拉了回来。噬菌体通过与特定的细菌菌株结合，从而杀死细菌治疗疾病（图源BiomX官网）后抗生素时代，这对夫妇利用噬菌体疗法成功打倒了超级细菌，同时，这也给世人敲响了一记人类滥用抗生素的警钟。书中所涉及的抗生素耐药性（Antibiotics Resistance, ABR），是指细菌对于抗菌药物作用的耐受性。耐药性一旦产生，药物的化疗作用就会明显下降。如果长期应用抗生素，占多数的敏感菌株就会不断被杀灭，耐药菌株则会大量繁殖，代替敏感菌株，而使细菌对该种药物的耐药率不断升高。抗菌素耐药性（Anti-Microbial Resistance, AMR），则是指病原体（细菌、病毒、真菌等）不能被抗生素及其他抗感染药物有效杀死的抵御能力。近几年，这一概念逐渐取代了原先的抗生素耐药性概念，全面涵盖了大部分传染性疾病中的耐药性，因而被各大国际卫生研究组织所采用。对于普通人来说，这些概念也许显得官方且陌生。但早年间大家将阿莫西林、诺氟沙星等抗生素当成万金油使用，近年又提及抗生素就色变的这种两极转变，就是大众滥用抗生素造成耐药性产生的苦果。据“联合国抗菌素耐药性特设机构间协调小组”截至2019年发布的报告显示，全球每年至少有70万人死于耐药菌感染。如果不加以控制，到2050年这一数字将攀升至1000万，与目前每年死于癌症的人数相当，对经济的破坏可与2008—2009年的全球金融危机相提并论。另据世界卫生组织估计，这一问题每年在欧洲造成的费用高达70亿欧元，在美国为65亿欧元。抗菌素耐药性，已逐渐成为一个日益严重的公共卫生问题，噬菌体疗法则将成为破局的关键。噬菌体，是一类专门杀死细菌的病毒，存在于多数原核生物中，主要由蛋白质和核酸组成。噬菌体可能是生物圈中数量最丰富的生物，其数量比菌群的其他成员如细菌多10^4倍。理论上讲，噬菌体总量在10^31左右，超过其他所有生物体的总和，是维系生态系统中的细菌数量的决定性力量。这意味着，每一种细菌都有多种噬菌体能够杀死它们。噬菌体疗法除了治疗细菌感染之外，近年来，随着合成生物学、生物信息学、大数据和AI等学科的兴起，其在药物发现、诊断和材料科学等领域也在不断开疆扩土，可开发形成无机纳米结构、诱导干细胞分化的平台、检测疾病的生物标志物、组织再生结构支架等。根据Databridge MarketResearch发布的研究报告预计，在2021年至2028年期间，全球噬菌体治疗市场的市场价值将会以16.76％的复合年均增长率增长。另一家咨询公司Coherent MarketInsights也曾发布过类似的预测结果，认为噬菌体治疗市场将在未来得到显著的发展。浓厚“以色列”背景，CEO曾参加“Talpiot”计划不仅行业内多个机构发布数据，预测噬菌体疗法市场前景良好，这一赛道还屡次获得官方机构的重视。文中所讲述的BiomX公司，其背后就有不少知名投资机构、药企和官方组织。作为头部噬菌体企业，BiomX成立于2015年，并于2019年上市，其总部位于以色列。BiomX噬菌体疗法的开发主要基于先进的噬菌体展示技术（Phage Display Technology)、噬菌体培养、计算生物学与合成生物学。此外，BiomX在化妆品和肠道药物等领域也有涉足。BiomX通过与位于以色列雷霍沃特的Weizmann Institute of Science（魏茨曼科学研究所）合作，基于Rotem Sorek博士、Eran Elinav博士及Timothy K. Lu博士等科研人员的前沿创新研究开发新型噬菌体。除了创始团队大牛云集之外，BiomX的管理团队也大有来头。仅以首席执行官兼董事会成员Jonathan Solomon为例讲述。在BiomX任职之前，Solomon是CNS先驱企业ProClara（前身为NeuroPhage）的联合创始人、总裁兼首席执行官。在他的领导下，该公司曾筹集了1亿多美元，并启动了一项正在进行的与阿尔茨海默病相关的临床试验。此前，Solomon还曾被选中参加以色列国防军精英“Talpiot”（塔楼）计划，在毕业时担任班级告别演讲者，并在机密军事单位服役 10 年。Solomon拥有希伯来大学物理和数学学士学位，特拉维夫大学电气工程硕士学位，以及哈佛商学的工商管理硕士学位。“Talpiot” 计划每年会挑选最顶尖的2%的高中毕业生送往大学学习科学和工程，而后在2年的服兵役期间继续在该领域内进行深入学习，从该项目毕业的近三分之二人员成为以色列顶级学术专家与成功企业的创始人。以色列义务兵役制度是“任务导向型”教育方式的完美示例，这也是Solomon“文武双全”的主要原因。该国的大量退役者在获得相关的教育培训后成立了超过1000 家公司，包括即时通讯开创者ICQ、安全巨头Palo Alto Networks、网络数据公司Onavo（被Facebook收购），以及微软Kinect 技术背后的3D视觉公司PrimeSense（被苹果收购）等。根据动脉网资料显示，以色列拥有5000多家高科技企业，科技创新对GDP的贡献超过90%。谷歌前董事长埃里克·施密特曾称赞以色列是“仅次于美国的世界最重要的高科技中心”。在生命科学领域，以色列表现得尤为突出。过去十年，以色列平均每年新成立139家生命科学领域企业，发展态势迅猛。其中，医疗器械是以色列最为发达、商业化最高的行业之一，根据数据显示，以色列共有725家医疗器械公司，占整个行业公司数量的53%，庞大的市场体量使得以色列成为了世界第二大医疗器械供应国。身处全球医疗创新强国，BiomX自然发展迅速。根据crunchbase信息显示，BiomX成立至今一共完成了6轮融资，融资金额累计超1.3亿美元，投资方包括武田风投、奥博资本、强生、Deerfield、日本SBI基金、Seventure 基金等知名投资机构。BiomX融资历史，数据来源crunchbase此外，被BiomX合并的企业APT的背景也不可小觑，其噬菌体库来源于美国海军实验室。根据crunchbase数据显示，其投资方包括美国国防部、美国国防卫生局、梅奥诊所等大家熟知的机构。APT还在2023年入选了“生物技术猛公司”榜单。建立两大技术平台，与强生和BI合作在团队和资本的联合助力下，目前BiomX建立了XMarker生物标志物发现平台以及BOLT噬菌体治疗平台（BacteriOphage Lead to Treatment）。XMarker平台使用独特的基于宏基因组学的方法来发现预测性微生物基因组特征，基于这些特征，可以进一步发展成生物标志物。该平台结合了超高分辨率 DNA 分析、人工智能技术和大规模云计算基础设施，以构建高灵敏度和特异性的分类菌库。该平台的人工智能技术来源于魏兹曼科学研究所 Eran Segal 教授开发的算法。2017 年，BiomX 公司收购了一家名为 RondinX 的公司，以进一步完善该算法。目前，强生和勃林格殷格翰正在基于XMarker平台与BiomX开展合作，前者主要是与BiomX共同开发炎症性肠病（IBD）诊断性生物标志物，后者则是开发IBD相关的生物标志物。BOLT平台由计算工具、自动筛选、合成工程等各个板块组成，可开发针对特定致病菌的天然或工程噬菌体疗法，具体开发路径有以下两条：BOLT平台开发路径，图源BiomX官网个性化噬菌体疗法，指在 6-8 周内针对特定患者的目标菌株量身定制。该疗法可为多个患者并行运行此类生产套件，可在项目启动后的 12-18 个月内进行临床个性化概念验证。通用型噬菌体疗法，指针对细菌宿主范围、耐药性和其他因素进行了优化，以针对广泛的患者群体开发相应的产品。基于上述技术平台，BiomX目前能够实现目标细菌发现、噬菌体合成、产品开发和生物标志物发现等一系列工作。本次合并APT后，BiomX吸引了大量非稀释性政府资金，包括从美国国防卫生机构、美国国立卫生研究院和其他机构获得了超过4000万美元的资金，还获得了大型噬菌体库等各类资源。基于这些资源，BiomX将重点推进BX004和BX211这两条经过改造的细菌杀伤病毒管线。主要在研管线，图源BiomX官网其中，BX004管线，是BiomX开发的、针对囊性纤维化（CF）患者慢性铜绿假单胞菌感染的、噬菌体鸡尾酒药物管线。2023年8月，FDA授予了BX004快速审评通道资格。在此前的Ⅰb/Ⅱa期试验中，数据显示BX004具有良好的安全性和有效性。2023年11月底，BiomX宣布第二部分试验取得积极结果。该药物在今年年初获得了FDA孤儿药资格认定，其Ⅱb期研究数据预计将在2025年第三季度公布。BX211（原代号APT.DFI.001）则是APT开发的个性化噬菌体库疗法，用于治疗糖尿病足骨髓炎（DFO）中的金黄色葡萄球菌感染。据美国糖尿病协会估计，在庞大的糖尿病人群中，有20%的糖尿病足感染患者（其中60%以上感染严重），如果不及时治疗，严重者可能需要截肢。面对这一庞大的市场，BiomX正在加足马力推进BX211管线，预计其安全性、耐受性和疗效研究初步结果预计将于 2025 年Q1公布。国内政策频发，全球交易不断当一个赛道只有一家企业在奋力前行时，这个领域肯定存在某些限制发展的问题，只有产业链共同发展才能正向推动行业前进。相较于重磅交易频频爆出的ADC、CGT等新兴赛道，噬菌体赛道也有属于自己小而美的各类产业消息。去年11月，噬菌体疗法入选了国际纯粹与应用化学联合会（IUPAC）的“化学领域十大新兴技术”榜单。此外，除了前不久BiomX与APT合并之外，近几年行业内还有数起噬菌体企业收购、并购案件引人关注。2023年6月，法国噬菌体公司Pherecydes pharma与红细胞递送抗肿瘤疗法公司Erytech合并，双方各占新公司约49.5%和50.5%股权，新公司更名为Phaxiam，重点推进针对金黄色葡萄球菌、大肠埃希菌和铜绿假单胞菌的噬菌体疗法。2021年11月，BioNTech以1.5亿欧元收购奥地利噬菌体公司Phagomed，这是噬菌体药物开发领域的一笔大规模交易，也流露出大药企对噬菌体技术的认可。2019年5月，美国噬菌体公司AmpliPhi Biosciences与抗菌肽公司C3J Therapeutics完成合并，双方各占新公司76%和24%股权，新公司更名为Armata Pharmaceuticals，重点推进针对铜绿假单胞菌和金黄色葡萄球菌的噬菌体疗法。目前，在海外，除了上面提到的三家企业和BiomX之外，还有Intralytix、Locus Biosciences、EnBiotix、Micreos等数家企业布局该赛道，国内也有诺安百特、菲吉乐科、上海高科、艾美诚信、艾柏森生物、希拓生物等企业布局该赛道。根据公开资料不完全统计，国内目前布局噬菌体医疗赛道的企业除了上述企业之外，国内还有许多农业领域的企业布局该赛道，官方亦陆续出台了不少鼓励的政策。2023年8月，中国噬菌体研究联盟、中国生物工程学会噬菌体技术专业委员会、中国微生物学会医学微生物与免疫学专业委员会组织了国内一线噬菌体领域及临床专家、学者及产业界代表共同商讨并撰写了国内首部噬菌体专家共识。此外，为了能够更好地服务于噬菌体治疗及预防使用、满足噬菌体研究的科研需求、实现噬菌体资源共享，国内相关领域内专家还共同起草了《预防及治疗用噬菌体质量标准专家共识》，对入库噬菌体的来源、宿主、生物学特性及入库噬菌体的包装与标识等提出建议，加速推动噬菌体的研究、转化及临床应用，该共识于2023年11月17日在《中国生物工程杂志》网络首发。根据公开资料不完全统计，我国近年颁布的与噬菌体相关的政策在产业链各个环节都协同发力的情况下，国内噬菌体行业在近年的确发展迅速。但不可否认，目前我国并无噬菌体治疗的专项监管法规。国内开展噬菌体治疗主要通过申请研究者发起的噬菌体治疗临床试验，在符合条件的医疗机构开展。目前，全国仅有上海市公共卫生临床中心、中山医院、上海嘉会医院、深圳三院等少数几家医院开展了噬菌体治疗临床试验。噬菌体疗法的发展还道阻且长。但在这个各类细菌疾病肆虐的时代，噬菌体疗法一定会等来属于自己的产业曙光。* 参考资料：1.《“弹丸之国”以色列为何能跻身世界创新强国？》2.《Chinese expert recommendation on phage therapy in the clinical practice》动脉网第八届未来医疗100强大会现已升级为，将于2024年5月7日-10日在北京·北人亦创国际会展中心盛大举行。本届展会为15000+人次、10000平规模，围绕新产品、新技术、新服务、新生态、新合作构建体系，为医疗健康产业的创新力展示搭建最佳舞台。这里是，公认的医疗产业创新洞察的生成地，年度趋势分享与学习交流的口碑盛会；优秀的医疗创新企业和创新产品都在这，是企业展示创新和面谈合作的最佳场景；这里有，最具前瞻力的思享盛会：500+大咖嘉宾莅临分享，3天主论坛、40余场主题论坛，只做干货议题！最具创新力的生态链接：5大展区，200+首发首创新品、3000+企业、500+投资团，全球买手云集！最具影响力的榜单发布：上市公司创新力榜+未来医疗100强榜+创新力产品榜，700+上榜企业现场交流！目前已有超过600家企业和产品确认参加展会，展览面积预订超过70%，全球买手团已合作了印度尼西亚、新加坡、比利时、爱尔兰、西班牙、德国、澳大利亚、英国、加拿大等国家。余下的合作席位已不多，欢迎企业、品牌方、买手团或相关组织洽谈参会。在这个充满不确定性的时代，寻求高价值资源和高效率链接，将是您的首选。即刻报名，限时福利！声明：动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。未经许可，禁止进行转载、摘编、复制及建立镜像等任何使用。动脉网，未来医疗服务平台

微生物疗法临床研究基因疗法

2021-07-21

·GlobeNewswire

Phage Therapy Market Globally is Expected to Foresee a CAGR

Patna, July 21, 2021 (GLOBE NEWSWIRE) -- Antibiotics resistance has now become one of the biggest challenges globally for the healthcare industry; thereby, giving rise to extensive research across phage therapy market. Overuse of antibiotics to any age group would result in antibiotics resistance and serious health problems, so the scientists across the globe are working hard to replace traditional use of antibiotics by modernized phage therapy or also called bacteriophage. Further, increasing application of bacteriophage across food & beverage industry, rise in incidences of food-borne diseases, extensive research and development, use of bacteriophage to treat target bacteria and increase in antimicrobial resistance are some of the major factors boosting the growth of phage therapy market globally across the U.S., Asia-Pacific, Europe, South America, Middle East and Africa. Extensive research & development is on the way to discover cure to many of the severe diseases which could only be treated with antibiotics. Ongoing clinical trials of phage therapy to cure diseases such as Urinary Tract Infection Bacterial, Prostate Cancer, Acute Tonsillitis, HIV Infection, Wound Infections, Mild Gastrointestinal, Primary Immune Deficiency Diseases, Venous Leg Ulcers, Covid19, Tuberculosis, Cystic Fibrosis, Bacterial Infections and many others would open up a new scope in the coming years where antibiotics treatment could be replaced with phage therapy. However, reliability is still a concern as this therapy is still under clinical trials and company pipelines along with the absence of experts, specialists and prepared technicians. Global phage therapy market also called bacteriophage therapy market is segmented into: by bacteria type, by product, by application, and by geography. By bacteria type, the scope of the report includes Salmonella Bacteriophage, Streptococcus Bacteriophage, Escherichia Coli and Others. By Product, the segments covered are oral consumption, external consumption and surgical treatment. By application, the report covers human medicines, veterinary sciences, food & beverage and Others (Agriculture, Dentistry, etc.) Geographically, North America hold the major share at present and is expected to lead this market globally over the next seven years, reason being the early adoption of new and emerging technologies coupled with expanding volumes of data. However, Asia Pacific is expected to witness the highest CAGR in the phage therapy market. Across applications, the food segment leads the global market at present. Looking for a Customized Report? Enquire at There are several companies operating in the phage therapy market investing and focusing on developing advanced bacteriophage platforms. For instance, Armata Pharmaceuticals, Inc. Adaptive Phage Therapeutics, Phagelux, SNIPR BIOME, Microgen Russia, BiomX (MBcure Ltd.), Enbiotix, Eligo Bioscience, MicroPhage Inc., Phage International, Intralytix, Inc, InnoPhage, iNtODEWorld, Locus Biosciences, Bitbiome, PhagoMed Biopharma GmbH, Pherecydes Pharma SA, TechnoPhage, Eliava Biopreparations Ltd., Nextbiotics, PhagePro, Inc, Phi Therapeutics, Fixed-phage Ltd, Micreos BV, and ContraFect Corporation among other are the leading players in the global phage therapy market. Moreover, the emerging economies across the globe are providing thriving opportunities across the global phage therapy market and the major reason is the increasing patient population in the health care sector globally. Related Reports we have on Healthcare Industry: Phage Therapy in Food Safety Market by (Virus and Bacteria), By Key Players (Phage Therapy Pipeline, Human Phage Therapy Diseases and Respective Bacteria, 2021-2027), By (Region and Country) - Global Industry Scenario, Analysis, Size, Share and Forecast, 2019 – 2028 Gamma Knife Market by Indication (Brain Metastasis, Arteriovenous Malformation (AVM), Trigeminal Neuralgia, Movement Disorders, Cancer, Others), By Geography and Country (the U.S., APAC, Europe, RoW) - Global Industry Scenario, Analysis, Size, Share and Forecast, 2019 – 2027 Ambulatory Blood Pressure Monitoring (ABPM) Market by Product (Arm ABPM, Wrist ABPM), by End User (Hospitals, Ambulatory Surgical Centers, ASCs), By Geography and Country (the U.S., Europe, APAC, RoW) - Global Industry Scenario, Analysis, Size, Share and Forecast, 2019 – 2027 Spine Surgery Robots Market by type (Minimal Invasive Surgery, Open Surgery); by application (Disc Replacement, Spine Fusion); by Region/ Geography/ Country (North America, Europe, Asia Pacific, Rest of the World (RoW) - Global Industry Scenario, Analysis, Size, Share and Forecast, 2019 – 2028 Ozone Sterilizer Market by type (Fixed, Mobile); by application (Medical Devices, First Responder, Sports Equipment, Food, Air Treatment, Vehicles, Others); by Other Technologies (UV Sterilizer, Photo Catalyst, Plasma Technology); by Geography (the U.S., Europe, APAC, RoW) - Global Industry Scenario, Analysis, Size, Share and Forecast, 2019 – 2028 About Us Accurize Market Research (AMR) is a full-service market research and business-consulting company which provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Industry Intelligence Solutions”. AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.” Destined by the dedicated team of analysts and experts, we are envisioned to provide you our best in order to plan your next strategic across several industry verticals. We at Accurize Market Research provide syndicated as well as customized reports across domains namely Consumer Goods, Food & Beverages, Manufacturing, Medical Devices, Mining Equipment, Automation, Manufacturing, Healthcare & Medical, and Defense & Aerospace, Semiconductor & Electronics, Construction, Information and Communication, Construction, Banking, Financial Services and Insurance (BFSI), and Energy among others. These industry vertical areas are further studied and analyzed across different geographies namely North America, Europe, Asia Pacific and Rest of the World (RoW). The countries across these major geographies are also covered under the scope of our study; such as the U.S., Mexico and Canada under North America; UK, Germany, Russia, Germany and France among others under Europe. Similarly, China, India, Taiwan, South Korea, Australia, Singapore and Japan among others are covered under Asia Pacific. Rest of the World (RoW) includes South & Central America, Middle East and Africa. Further, as per the scope countries across South & Central America, Middle East and Africa would also be studied separately under the scope of the report. Available Report Format: Excel/PDF/PPT/Word Contact: Rakesh K Singh Head - Business Development Patna Office (Asia): K-129, PC Colony, Hanuman Nagar, Kankarbagh, Patna, PIN - 800020 Tel: +1-339-368-6383/ +91-9665120699 Email: help@accurizemarketresearch.com Web: Accurize Market Research Blog:

100 项与 Intralytix, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Intralytix, Inc. 相关的转化医学

登录后查看更多信息